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Transient receptor potential melastatin 8 (TRPM8), a nonselective cation channel, is the predominant 
mammalian cold temperature thermosensor and it is activated by cold temperatures and cooling 
compounds, such as menthol and icilin. Because of its role in cold allodynia, cold hyperalgesia and 
painful syndromes TRPM8 antagonists are currently being pursued as potential therapeutic agents for 
the treatment of pain hypersensitivity. Recently TRPM8 has been found in subsets of bladder sensory 
nerve fibres, providing an opportunity to understand and treat chronic hypersensitivity. However, 
most of the known TRPM8 inhibitors lack selectivity, and only three selective compounds have reached 
clinical trials to date. Here, we applied two virtual screening strategies to find new, clinics suitable, 
TRPM8 inhibitors. This strategy enabled us to identify naphthyl derivatives as a novel class of potent 
and selective TRPM8 inhibitors. Further characterization of the pharmacologic properties of the most 
potent compound identified, compound 1, confirmed that it is a selective, competitive antagonist 
inhibitor of TRPM8. Compound 1 also proved itself active in a overreactive bladder model in vivo. Thus, 
the novel naphthyl derivative compound identified here could be optimized for clinical treatment of 
pain hypersensitivity in bladder disorders but also in different other pathologies.
Transient receptor potential (TRP) channels are a group of ion channels located primarily on the plasma mem-
brane of numerous animal cell types1, 2. These channels are characterized by six transmembrane subdomains 
flanked by intracellular C- and N-terminal regions, and they are capable of homo- or hetero-tetramerization to 
form cation-permeable pores3. These channels mediate responses to a wide range of stimuli, such as pain, heat, 
warmth or coldness, as well as taste, pressure, and vision. Members of the mammalian TRP channel family can 
be subdivided into seven classes according to their sequence homology: TRP ankyrin (TRPA), TRP canoni-
cal (TRPC), TRP melastatin (TRPM), TRP melastatin-like (TRPML), TRP NOMPC (TRPN), TRP polycystic 
(TRPP) and TRP vanilloid (TRPV). Eight of the family members are recognized as thermo-TRPs in that they are 
expressed in primary somatosensory neurons and are activated at specific temperatures ranging from noxious 
heat to painful cold. TRPV1–4 transduce elevated temperatures ranging from warm (TRPV4 and TRPV3) to 
noxious heat (TRPV1 and TRPV2). By contrast, TRPM8 and TRPA1 are activated by moderate and more extreme 
cooling, respectively. All thermo-TRPs are also activated by a wide range of natural compounds. TRPM2, TRPM4 
and TRPM5 also show temperature sensitivity but are not usually included in the thermo-TRP family because 
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they are not expressed in primary somatosensory neurons4. TRP channels are not particularly closely related by 
either structure or function. In fact, the most similar TRPM channel to TRPM8 is TRPM2, but this channel is 
involved in oxidative stress sensing and is expressed in dopaminergic neurons and other tissues in which TRPM8 
is not present5, 6.
Transient receptor potential melastatin type 8 (TRPM8) is a member of the transient receptor potential (TRP) 
superfamily2. More specifically, TRPM8 is a ligand-gated, nonspecific cation channel that is activated by cold tem-
peratures, by natural cooling compounds, such as menthol and eucalyptol, and by synthetic agents, such as icilin7.
TRPM8 expression defines a population of sensory afferents that innervate tissues known to be highly sensitive 
to cold stimuli, as well as nociceptive stimuli8. In addition, the localization of TRPM8 on nociceptive A-delta and 
C-fiber neurons and its modulation by inflammation-mediated second messenger signals, may account for abnor-
mally cold sensitivity in some pathologic states, providing a good molecular basis and a rationale for the design 
of TRPM8 antagonists9. Indeed, characterization of TRPM8 has revealed its role in pain hypersensitivity10, 11  
that is manifested in two forms: cold allodynia and cold hyperalgesia12. Cold allodynia refers to pain induced by a 
normally innocuous cold temperature, and is one of the main clinical symptoms experienced by patients under-
going chemotherapy. It can also occur in patients with other conditions such as diabetic neuropathy13, fibro-
myalgia, and traumatic neuropathy11. Cold hyperalgesia, in which a noxious stimulus results in a prolonged or 
intense pain response, commonly occurs with chronic inflammation14, such as in rheumatoid arthritis15. During 
the time, many other painful conditions have been related to TRPM8 activity. The recent discovery of different 
receptors in the bladder, in subsets of sensory nerve fibres, responsive to temperature or molecules as capsaicin 
and menthol provides an opportunity to understand and treat TRPM8-related bladder painful disorders. For 
example, TRPM8 has been related to the painful or overactive bladder syndromes (OBS) ad painful bladder (PBS) 
or overreactive bladder syndromes16. PBS is a chronic bladder hypersensitivity disorder which causes suprapubic 
pain along with an increased micturition frequency and nocturia, while OBS is characterized by urinary urgency 
with or without urge incontinence and increased frequency17. Additionally, an immunohistochemical study has 
shown that the density of the TRPM8 channel protein is elevated in bladder afferent nerves in overactive bladder 
patients compared with normal subjects18. Moreover, there is a positive correlation between TRPM8 density and 
voiding frequency18. Altogether these findings suggested that TRPM8 could be a promising target to develop 
drugs to treat different painful disorders19, 20. Known TRPM8 antagonists primarily belong to the chemical classes 
of para-menthane-based or non-para-menthane-based ligands21–23, depending on the presence of the menthol 
scaffold. Many of these TRPM8 antagonists, such as BCTC24, CTPC25, and capsazepine26 are also antagonists of 
other TRP channels, particularly TRPV1 and TRPA1, thus suggesting a conserved mechanism for the ligand 
activation of these thermosensitive TRP channels27–30. This overlapping mechanism of activation makes the iden-
tification of selective agents for these ion channels difficult. To date, only three TRPM8 antagonists have reached 
clinical evaluation: the quinolone- and pyridine-carboxamide derivatives PF-05105679 (Pfizer; ClinicalTrials.gov 
Identifier: NCT01393652) and AMG-333 (AMGEN; ClinicalTrials.gov Identifier: NCT01953341), which entered 
but did not pass phase I studies30, 31, and the cannabinoid Cannabidivarin (GWP-42006) (GW Pharmaceuticals; 
ClinicalTrials.gov Identifier: NCT02365610), which is currently in phase II clinical study31, 32. Thus, the need for 
novel TRPM8 inhibitors is urgent and many companies and researchers are working on this target.
Currently, virtual screening plays a key role in the discovery of novel drugs, representing a cost-effective and 
efficient method to increase hit rates compared to wet-lab high-throughput screening (HTS)33–36. Virtual screen-
ing techniques can be subdivided into ligand-37, 38 and structure-based39, 40 approaches; the former is mainly 
based on similarity analyses and the latter mostly involves docking simulations. Recent studies have indicated the 
possible fruitful combination of both methods41.
Here, with the aim to discover novel TRPM8 inhibitors, we used a combination of ligand- and structure-based 
approaches to screen a proprietary library of 124,107 highly diverse compounds. Promising active molecules (a 
total of 11,725) were then subjected to conventional wet-lab screening using the calcium-sensitive fluorescent dye 
approach42, 43. This approach enabled the identification of a set of naphthyl derivatives as new potent and selective 
TRPM8 inhibitors (US8906946, Dompe’ SpA 2014). Among this set, compound 1 was identified as a selective 
TRPM8 inhibitor, with potency in the nanomolar range and a competitive mode of action. We tested compound 
1 in preliminary in vivo tests using an isovolumetric bladder rat model to assess its possible usefulness in painful 
and overreactive bladder syndromes44. We observed that compound 1 had a positive effect on inhibition time, 
threshold bladder volume-inducing rhythmic bladder contraction (RBC) and micturition frequency (MF). Taken 
together, our results suggest that compound 1 could be a good candidate for the development of clinical suitable 
drugs for the treatment of urologic disorders as PBS or OBS.
Methods
Pharmacophore mapping. Pharmacophore feature extraction was performed using the Smiles Arbitrary 
Target Specification (SMARTS) language45 to encode the structure-activity relationship of a selection of struc-
turally unrelated TRPM8 antagonists, as schematized in Fig. 1. SMARTS queries are commonly used in the defi-
nition of molecular motifs and have a wide application in sub-structures filtering, such as flagging toxicological 
structures in library screening46. First, SMARTS language was used to encode the structure-activity relationship 
on a selection of structurally unrelated TRPM8 antagonists, as schematized in Fig. 1. Subsequently, SMARTS 
queries were extended to include additional chemical motifs not represented in the reference set and to exclude 
undesired chemical moieties. Together, these derived SMARTS queries were used to virtually screen a proprietary 
database and to generate a ligand-based targeted library of putative TRPM8 antagonists.
To date, approximately 120 different chemotypes can be enumerated among all known TRPM8 antagonists 
(as defined by Bemis et al.47). To represent this wide chemical spectrum, 12 structurally diverse TRPM8 antag-
onists were selected for pharmacophore development, each reporting on a characteristic structural moiety and 
spacing in molecular flexibility and ring heterogeneity (size and complexity), as well as accounting for different 
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polar groups (Figure S1). As shown schematically in Fig. 1A the resulting pharmacophore consisted of a hydrogen 
bond acceptor system (HBA) and a hydrogen bond donor system (HBD) between two terminal rings with vari-
able length spacers separating each functional group (Fig. 1B). This general motif, in addition to covering the 12 
selected antagonists, included approximately 50 of the abovementioned TRPM8 antagonist chemotypes.
In more details, the HBA group is represented by direct and reverse sulfonamide, ether, ester, ketone and 
imine groups, whereas the HBD group is represented by amido, amino and hydroxyl groups. In the twelve 
selected TRPM8 antagonists (Figure S1), the two H-bonding groups can be spaced by the following number of 
atoms: (i) one atom, as in the case of compounds 1, 6, 8, 10 and 11; (ii) two atoms, as for compounds 3, 5, 9 and 
12; or (iii) three atoms, as in compounds 2 and 7. This pattern, which condenses the structure-activity relation-
ships among the active hits, can be encoded by three SMARTS strings (Fig. 1B). Considering the constrained 
systems it has been proposed that the cis orientation is preferred, which is consistent with the proposed binding 
mode for TRPM8 inhibitors on the basis of the derived 3D homology models of the ion channel (Fig. 2). One of 
the 12 antagonists selected and presented in Figure S1, the fourth, by Bayer, despite having five atoms separating 
the two H-bonding functions, was included in the set because the high flexibility of the ethylamine chain (HBD) 
can approach the para-ether group (HBA), thus “spatially” matching the pharmacophore. Up to two atoms are 
allowed between the terminal ring and the HBA group, whereas a maximum of one atom is permitted between 
HBD and the other ring. Either aromatic or aliphatic rings are allowed and can include the H-bonding function.
To further enlarge the selection to encompass different scaffolds, the pharmacophore was extended to include 
other HBA or HBD groups. Additionally, a collection of more than 200,000 biologically relevant compounds 
from the MDDR Database48 which are already annotated for their chemical structure, physicochemical prop-
erties and biological activity. This collection was then analyzed to identify chemical moieties sharing the same 
pharmacophore, although with different biological activities and different chemotypes. Chemical moieties with 
undesired mechanisms of action (or specific targets) were excluded. Using the same rationale used to define 
the pharmacophore model, a total of 37 SMARTS strings related to the undesired moieties were defined (seven 
representative SMARTS are presented in Table S2). After the optimal set of SMARTS strings was defined, they 
were used to screen the corporate library to identify TRMP8 blockers while discarding nonselective or undesired 
scaffolds and maximizing chemical diversity.
Structure-based virtual screening strategy optimization. We used already known TRPM8 inhibitors 
to develop a docking-based screening strategy on the TRPM8 receptor structure. For this purpose, we collected a 
benchmarking set comprising 50 published TRPM8 antagonists22 and 4,950 decoy compounds taken from known 
inactive compounds, as identified in previous HTS campaigns (data not shown). To avoid bias in the results, 
inactive compounds were selected only if they fulfilled several physicochemical property ranges, as determined 
by analyzing the active compounds.
The obtained compound set was used in preliminary docking simulations on a previously published human 
TRPM8 homology model49. We used a homology model generated by fragments of the resolved structure of the 
Kv1.2 Shaker channel as the overall template50. To date, the only additional structure available is the recently 
resolved TRPV1 structure51; however, TRPV1 does not have a significantly high degree of similarity with TRPM8 
with respect to our model (pairwise alignment BLOSUM62 score 0.39 vs 0.35)52. Moreover, TRPV1 structure 
allows for reliable generation of only the transmembrane bundle. The Kv1.2 Shaker channel remains reliable for 
modeling the binding site within the transmembrane bundle in an unbound conformation, as supported by the 
positive results obtained in previous publications45, 49, 52–54 as well as by the satisfactory docking results reported 
here. Both the benchmarking set and the virtually screened library were prepared using an automatic script in 
the VEGAZZ suite of programs55, which performs the following tasks for each compound: (i) generating the 3D 
structure; (ii) adding the hydrogen atoms; (iii) assigning the atom types and the Gasteiger’s atomic charges; (iv) 
Figure 1. Derived pharmacophore through SMARTS strings. (A) Schematization of the derived 
pharmacophore model. (B) SMARTS strings encoding for the pharmacophore.
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selecting the predominant form of ionizable molecules at physiological pH; (v) generating all possible stereoi-
somers for chiral molecules; and (vi) minimizing the obtained molecules by combining steepest descent and 
conjugate gradient algorithms.
Docking simulations were performed using the LiGen50, 56 program and were optimized by tuning the 
arrangement and the extension of the box where the docking search was performed. Note that the dock-
ing parameters of the program were not adjusted because they had already been optimized by experimental 
design in a previous study, thus maximizing virtual screening performance50. Before performing docking sim-
ulations, LiGen requires the development of a suitable pharmacophore model by using LiGenPocket. To this 
end, a relatively large and highly potent TRPM8 antagonist (Cpd 13 WO2007017094, belonging to the class of 
benzyloxy-phenylmethylcarbamates with an IC50 = 0.45 nM) not included in the benchmarking set was utilized 
to avoid biasing results and to develop the pharmacophore as exhaustively as possible.
To the best of our knowledge, experimental evidence indicates that TRPM8 antagonists bind the 
menthol-binding site of TRPM8 to exert their action. Hence, the LiGen simulations were focused on the 
menthol-binding site and were tuned by varying the radius of the considered sphere (i.e., equal to 12, 10, 8, and 
6.5 Å) and its center (around Asp802 or Tyr745) to also evaluate possible adjacent sub-pockets. The ligand was 
flexible, and the results were ranked on the basis of the LigenScore function. Figure 3 shows that the active com-
pounds are satisfactorily distributed across the entire rank (subdivided into 100 bins) and that the enrichment 
factors obtained by the best-performing LiGen simulation involved an 8 Å radius sphere around Asp802.
In vitro TRPM8 assays and high-throughput screening campaigns through analysis of intracel-
lular calcium mobilization. All experiments were performed on HEK-293/hTRPM8 cells stably transfected 
with the human TRPM8 gene, except for site-directed mutagenesis analysis, which was performed on transient 
transfectants57. In details, HEK-293 cells (ATCC, Manassas, Virginia) were transfected with the pcDNA3/
hTRPM8 vector by electroporation (300 Volts, 950 µF) then selected with medium containing 0,8 mg/ml G418 
for 10–15 days. Then the stable transfected pool underwent two rounds of limiting dilutions, in eight 96 well 
plates at a cell density of 1 cell/well, in order to obtain pure clones. The best responder clone was selected based on 
its response to 1 mM menthol in calcium mobilization experiments. HEK-293/hTRPM8 cells were maintained in 
EMEM (Minimum Essential Medium Eagle with Earl’s salts Balanced Salt Solution, LONZA) supplemented with 
2 mM Ultraglutamine1 (Lonza), 1% Penicillin/Streptomycin (LONZA), 10% of Fetal Bovine Serum (Euroclone) 
and 0,4 mg/mL G418 (InvivoGen).
For calcium mobilization assays, cells were seeded at 10,000 cells/well in 384-well plates coated with 
poly-D-lysine (MATRIX black/clear bottom #4332-CPL, Thermo Scientific, Waltham, MA, USA) in complete 
medium.Twenty-four hours after seeding, the plates were washed with Tyrode’s buffer with a Bio-Tek-ELx405 
Microplate Washer (Merck Millipore; Billerica, MA, USA), and then 10 µl/well of a solution containing the 
Figure 2. TRPM8-Compound 1 complex, detail of the binding site. (A) Top view, perpendicular to the 
membrane plane, extra- to intracellular perspective. The naphthyl moiety of the ligand, here highlighted in cyan 
and represented in CPK, well fits into the sub-pocket framed by Ile746, Tyr745, Leu750 and Leu806 (in grey 
and CPK). (B) Side view, perpendicular to the transmembrane helices. Compound 1, represented in cyan and 
ball-end-stick, lands parallel to TM helices 2 and 3 surface, here in red cartoon. Dotted blue line represents the 
Hydrogen bond between the amine group of Compound 1 and the carboxyl function of Asp802, interaction 
further strengthened by opposite charge attraction. The furane ring locates between Leu750 and Phe794 (in grey 
and CPK).
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fluorescent Ca2+ indicator Fluo-4 NW dye was added. Cells were incubated for 1 h at room temperature before 
test compounds were added at 3X the concentration with respect to the final wanted concentration to be tested 
with a FLIPR TETRA system (Molecular Devices, Sunnyvale, CA, USA). Calcium mobilization was monitored 
over a period of 5 min. A second injection of 10 µl/well of a reference agonist (icilin or Cooling agent 10) at 4X 
concentration in assay buffer was performed using the FLIPR TETRA system. Of note, for selectivity assays, the 
following agonists were used: 10 μM AITC (allyl isothiocyanate) for TRPA1; 100 nM Capsaicin for TRPV1; and 
20 nM GSK1016790A for TRPV4.
After addition of the agonist, the fluorescence signal was recorded over the next 3 min. The bioactivity exerted 
by the compounds was expressed as a percentage of inhibition. The percentage scale is defined as follows: 100% 
inhibition was considered as the relative fluorescence units (RFUs) of the value of the MIN controls in the second 
injection (antagonist Capsazepine at IC100 = 50 µM) and 0% inhibition was considered as the RFU values of the 
value of the MAX controls in the second injection (Cooling agent 10 at EC80 = 30 µM). Data from four replicates 
were analyzed using GraphPad PRISM® software (version 5, GraphPad Software Inc.) to calculate the mean 
and standard error of the mean, to create sigmoidal concentration-response curves and to calculate IC50 values. 
Agonist and antagonist concentrations for each calcium mobilization experiment are reported in Table S1.
Generation of TRMP8 single point mutation variants. Single point mutations were introduced in the 
hTRPM8-coding sequence, and the mutated TRPM8 was cloned as N-terminal c-myc tagged version into the 
pcDNA3 expression vector. This was done in that way that the single variations could be easily swapped from the 
myc-tagged expression construct into the non-tagged TRPM8 wild type expression construct.
The presence of the myc tag did not alter the functionality of TRPM8 receptor (data not shown). The list of 
the variants is the following: variant 1, t2233g, a2234c (=Y745A); variant 2, a2236g, t2237c (=I746A); variant 3, 
a2395g, a2396c (=N799A) and variant 4, a2405c (D802A). The cloning project comprised three steps. First of 
all, a unique XhoI restriction site was inserted by site-directed mutagenesis (SDM) using DNA of the pcDNA3_
TRPM8 construct as template. The 0.6 kb DNA fragment between the unique 5′ XhoI (introduced) and 3′ BamHI 
(already present) restriction sites comprised all positions of the four single point mutations and could be later 
used for their insertion as well as swapping between myc-tagged and non-tagged TRPM8 versions. In a second 
step, the c-myc tag sequence was introduced embedded within the TRPM8 coding sequence by PCR primers 
in two partially overlapping PCRs that were then joined by bridge PCR with the external 5′KpnI and internal 
3′EcoRI primers and in the last step the point mutations 1 to 4 were inserted into pcDNA3_c-myc-TRPM8 by 
exchanging the wild type 5′XhoI-3′BamHI fragment (0.6 kb) with each of the corresponding variation fragment 
derived from synthetic DNA (provided by GeneArt, ThermoFisher Scientific).The myc-tagged constructs were 
transiently transfected in HEK-293 cells with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol. The pcDNA vectors containing the wt myc-tagged TRPM8 gene and the empty pcDNA3 (mock) were 
separately transfected into HEK-293 cells as controls. Cells were transfected and seeded on the same day at 17,500 
cells/well in poly-D-lysine-coated 384-well plates (MATRIX #4332-CPL). Twenty-four hours after seeding, the 
activity of transfected TRPM8 receptors was tested using the calcium mobilization assay as described above. The 
analysis was performed on the basis of ΔF/F° (normalized MAX-MIN), where ΔF is the MAX between time 
points 117 and 182 minus the MIN between time points TP114 and TP116, and F° is the basal signal at time point 
TP0. The obtained data from at least four wells (as replicates) were analyzed with GraphPad PRISM® software 
Figure 3. Docking results obtained by LiGen on the benchmarking dataset. Distribution of the active 
compounds within the entire ranking as subdivided into 100 bins, resulting from the Docking campaign 
targeted in an 8 Å radius sphere around Asp802. Active compounds and enrichment factor (EF) are reported for 
each top N %.
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(version 5, GraphPad Software Inc.) to calculate the mean and standard error of the mean58, to create sigmoidal 
concentration-response curves and to calculate IC50 values.
Cold Stimulation Experiment. The cold stimulation assay was performed as previously described59. Cells 
were seeded at 1.5 × 106 cells in a T75 flask in complete medium. When cells were 80% confluent, the medium 
was removed, and cells were loaded by 5 ml flask of a solution of Screen QuestTM Fluo-8 NW dye (ABD Bioquest, 
Sunnyvale, CA, USA) added to the flask in a dark environment. Dye-loaded cell flasks were incubated for 45 min-
utes at room temperature in the dark. The Fluo-8 NW solution was then removed, and 10 ml of Tyrode’s buffer 
(5 mM KCl, 130 mM NaCl, 2 mM CaCl2, 5 mM NaHCO3, 1 mM MgCl2, 20 mM HEPES, pH7.4) was then added 
to the flasks; cells were detached by pipetting, counted by a cell counter, and then centrifuged and re-suspended 
in Tyrode’s buffer at 5 × 106 cells/ml.
Cells were then seeded in 96-well assay plates (MicroAmpTM Optical 96-Well Reaction Plates by Applied 
Biosystems, SG51811-5A, Part No. N801-0560) at 100,000 cells/well; test compounds at 5X concentration 
were manually added to the wells at a 5 µl volume, and the assay plates were incubated at room temperature for 
5 minutes; then, the experiment was performed using an ABI Prism® 7900HT Sequence Detection System (Life 
Technologies, USA).
The assay plates were initially held at 25 °C inside the instrument for 5 minutes, and the signal was recorded for 
2 minutes. The temperature was subsequently lowered to sub-physiological levels, and the signal was recorded for 
3 minutes. The raw results were analyzed for the extraction of the fluorescence data collected at starting and final 
temperatures, which were used to calculate a fluorescence difference (ΔF = fluorescence525nm at 14 °C – fluores-
cence525nm at 25 °C). The analysis was performed by computing ΔF/F0, where F0 is the fluorescence signal at the 
starting temperature (25 °C). IC50 (half maximal concentration) curves were generated by fitting the fluorescence 
data with a sigmoidal curve equation using GraphPad PRISM® software (version 5, GraphPad Software Inc.). 
All data point determinations were performed in duplicate before a mean value was calculated, and error bars 
represent the standard error of the mean.
Manual Patch Clamp Experiment. Sixteen hours before an experiment, cells were seeded onto 
poly-D-lysine-coated glass slides (150,000 cells each) and placed in 6-well plates in antibiotic-free medium. 
Immediately before experiments, the coated glass slides with seeded cells were washed five times with patch-clamp 
extracellular solution (145 mM NaCl, 10 mM EGTA, 10 mM HEPES, 10 mM Glucose, pH 7.4 with NaOH) and 
then placed into the recording chamber.
The electrophysiology study involved a whole-cell voltage clamp and intracellular solution consisting of 
128 mM CsCl, 10 mM EGTA, 0.7 mM CaCl2, 3 mM MgCl2, 10 mM HEPES, and 5 mM Na2ATP at pH 7.2 with 
CsOH. For the pulse protocols, cells were held at +40 mV, and outward currents were acquired in uninterrupted 
recording mode. Data were recorded in standard whole-cell voltage experiments performed at room temperature. 
For data acquisition and further analysis, an EPC10 digitally controlled amplifier was utilized in combination 
with PATCHMASTER software (HEKA Electronics, Lambrect, Germany). The EPC10 provides automatic sub-
traction of capacitive currents by means of the prepulse. The data were filtered at 2.9 KHz (−3 dB, 4-pole Bessel 
lowpass) and digitized at 100 µs per point. Liquid junction potential showed no correction. The input resistance 
of the patch pipettes was 2–5 MOhm, and the series resistances were carefully compensated up to 80%. Outward 
currents elicited by the addition of 50 μM cooling agent 10 or of cooling agent 10 (50 μM) plus compound 1 
(300 nM) were recorded.
In vivo experiments in isovolumetric bladder rat model. To assess the activity of compound 1 in 
preclinical models of painful urologic syndromes as OBS we used an isovolumetric rat bladder animal model. A 
preliminary PK/ADMET study was conducted to assess the behaviour of compound 1 in vivo (Table S3).
Female Wistar rats (190–250 g) obtained from Charles River Laboratories were housed according to animal 
welfare guidelines. Rats were housed in a specific-pathogen-free environment under strictly controlled light 
cycle conditions, and food and water were provided ad libitum. All experimental protocols were carried out by 
Urosphere in accordance with the European Community Council Directive 86/609/EEC. They were performed 
in accordance with French legislation concerning the protection of laboratory animals and they were approved 
by French Ministry for Agriculture and Fisheries which provided a currently valid license for experiments on 
vertebrate animals to Dr. Philippe Lluel.
For intravenous administration, compound 1 was diluted in vehicle (10% of 2:1 solutol:NMP, 16% buffer, and 
74% H2O) according to body weight to obtain doses of 10 mg/kg. For intravesical administration, compound 1 
was diluted at a concentration of 7.56 mg/ml in a solution of 7% 2:1 solutol:NMP, 11.2% buffer, and 81.2% H2O. 
Eight rats were used for the control group and eight were used for the treated group.
Rats were anesthetized with urethane (1 g/kg, i.p.), given as a divided dose of 80% initially and 20% 15 min 
later. After abdominal incision, the ureters were ligated and sectioned. A catheter was placed into the bladder 
through the urethra. Then, the urethra was ligated at the level of the urinary meatus. For cystometric experiments 
with intravenous compound 1 administration a bladder catheter was connected via a T-tube to a strain gauge, 
which was used to measure the intravesical pressure. Isovolumetric bladder contractions were induced by step-
wise injections of physiological saline at room temperature (100 μl every 5 min) until stable RBC occurred. After 
stabilization and a control period of at least 30 min, characterized by stable and reproducible bladder contractions 
(basal values), the test substance or vehicle was administered by intravenous infusion (1 mL within 5 min). The 
effects of compound 1 on micturition frequency (MF) (peaks/30 min), time of inhibition60, and threshold volume 
(ml) (volume inducing RBC) were analyzed. The drug effects were evaluated from the end of the administration 
up to 1 hour after administration. For intravesical administration, compounds were administered intravesically 
3 × 100 μl every 5 min. Then, the bladder was filled with 100 μl of saline every 5 min until the occurrence of 
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rhythmic bladder contraction (RBC) with a maximal volume of 3 mL. When RBC appeared, the intravesical 
pressure was followed over the next 90 min. Statistical analyses were performed using GraphPadPrism® 4.02. 
The results are presented as the mean values ± standard error of the mean58. For all tests, p < 0.05 was considered 
statistically significant.
For the intravenous administration results, basal values corresponded to the 30-min period before admin-
istration. Basal values of compound 1-treated groups and corresponding vehicle groups were compared using 
one-way ANOVA followed by Bonferroni test. One-way ANOVA with repeated measures followed by Bonferroni 
test was used to compare MF basal values with MF values post-administration in each group. Inhibition time and 
threshold volume in compound 1-treated and corresponding vehicle groups were compared using an unpaired 
Student’s t-test. For the intravesical administration results, MF values of compound 1-treated and corresponding 
vehicle groups were compared using two-way ANOVA followed by the Bonferroni test. Threshold volume values 
obtained in each group were compared using one-way ANOVA followed by the Bonferroni test.
Results
SMARTS-based (ligand-based approach) and Docking-based (structure-based approach) vir-
tual screenings. Since both ligand-based and structure-based approaches are limited by their own charac-
teristics we explored the possibility to use a combination of them to obtain a better search for TRPM8 inhibitors 
in in silico screening of the above cited proprietary library.
The SMARTS strings encoding the derived pharmacophore and those designed to filter undesired moieties 
were used to screen a corporate library of 124,107 compounds45 (see Supporting Information for details). As 
reported in Table 1, this analysis resulted in the selection of 6,400 molecules (20 × 384-well plates, 320 com-
pounds each plate), and the subsequent HTS analysis revealed that this selected subset included 479 confirmed 
hits (i.e., with a response score > 50).
Hence, the percentage of confirmed hits was 7.48% with an enrichment factor (EF) of 5.35, which was notable 
compared with the available random hit rate (1.4%) obtained in previous HTS studies. The ratio of scaffolds vs. 
active compounds of the selected set of compounds was 0.49, which was in line with that obtained by docking 
simulations (0.42; described further below). This result illustrates that suitably designed SMARTS strings can 
provide reasonably heterogeneous results that are not heavily constrained by the exploited pharmacophore rules 
(Table 1). The 10 best-performing SMARTS strings are reported in Table 2; notably, for all the reported strings, 
the k value was greater than 0, thus confirming that the obtained results were not due to a randomly correct 
prediction.
As for docking-based virtual screening, using the protocol described in the methods section, we screened the 
same corporate library of 124,107 compounds used in SMART-based screening (see Supporting Information 
for details), and the top-ranked 6,400 compounds were selected (the same number of compounds selected by 
SMARTS-based filtering). These 6,400 molecules were added to the compounds derived from the ligand based 
strategy, thus yielding a library of 11,725 diverse compounds that were subsequently analyzed by HTS.
Docking simulations indicated that TRPM8 antagonists simultaneously interact with both Tyr745 and 
Asp802; hence, the beneficial roles of a suitably spaced hydrogen bond acceptor (HBA), which interacts with 
Method Compounds Active Hit rate EF
Active Scaffolds (AS/
Compounds)
Total 11725 1030 8.78 6.27 483 (0.47)
Ligand-based 6400 479 7.48 5.34 238 (0.49)
Structure-based 6400 677 10.57 7.55 282 (0.42)
Consensus 1075 126 11.72 8.37 37 (0.29)
Table 1. Major results for the here performed virtual screening campaigns. The enrichment factors refer to a 










1 0.014 0.4 28.57 2 3 0,391
2 0.014 0.132 9.43 177 1164 0,120
3 0.014 0.127 9.04 10 69 0,114
4 0.014 0.104 7.41 11 95 0,091
5 0.014 0.093 6.66 11 107 0,080
6 0.014 0.088 6.31 25 258 0,075
7 0.014 0.08 5.71 24 276 0,067
8 0.014 0.079 5.67 17 197 0,066
9 0.014 0.063 4.48 14 209 0,049
10 0.014 0.052 3.75 275 4961 0,039
Table 2. Enrichment Factors (EF) and k values for the 10 SMARTS strings related to the pharmacophoric 
model (*K values computed as reported by ref. 46).
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Tyr745, and a hydrogen bond donor (HBD) system, which interacts with Asp802 (Fig. 2), were consistent with 
the conserved pharmacophoric features identified in the proposed ligand-based approach. The first cyclic sys-
tem should mimic the menthol carbon skeleton, whereas the second aromatic ring should approach Asn799. 
The interactions of both cyclic systems are strengthened by apolar contacts with the surrounding hydrophobic 
residues.
As reported in Table 1, there is limited overlap between the subsets selected via ligand-based and 
structure-based approaches; 1075 compounds are common to both sets (approximately 1/6 of the entire subset). 
This result suggested that SMARTS strings and docking simulations cover different chemical spaces owing to 
the different criteria through which the two methods select their molecules. Notably, the docking-based subset 
included 677 confirmed hits with an enrichment factor of 7.55, which was greater than that achieved by SMARTS 
strings. Interestingly, and contrary to what was expected, the docking-selected library showed chemical vari-
ability, as represented by a ratio of scaffolds per active compound that was comparable to that obtained using 
SMARTS strings (0.42 vs. 0.49). These results demonstrate that the extension of the pharmacophore overcome 
the limits of the atom mapping of the SMARTS encoding.
High-Throughput Screening. To confirm the biological activity of the compounds selected by above 
described in silico screening approaches, we performed a wet-lab HTS analysis of a focused subset of 11,725 
compounds. In the primary screen step, all 11,725 compounds were tested once at 10 μM. The screening quality 
parameter Z′ was evaluated for each plate both in the compound addition phase (CA; when the compound was 
applied to the cells) and in the subsequent target activation phase (TA; when the reference agonist was added 
at EC80 concentration to open the channel). An assay plate was considered valid in CA if Z′ was greater than 
0.4, whereas for TA, Z′ had to be greater than 0.5 (the HTS evaluation strategy is reported in the Supporting 
Information). Overall, the mean Z′ for TA was 0.77 with a standard deviation of 0.068, whereas for CA, the mean 
Z′ was 0.88 with a standard deviation of 0.06. Z′ prime calculation is based on the signal distribution of the posi-
tive and negative controls (MIN and MAX signals) allocated on fixed well positions on each plate.
Compounds active upon CA (potential agonists) and compounds that exhibited an unusual and rapid increase 
in the fluorescent signal upon CA (indicating potential auto-fluorescence) were flagged and excluded from fur-
ther characterization. The threshold for the primary screening hit selection was set at 50% inhibition. The primary 
screen identified 1727 compounds, corresponding to an impressive hit rate of 14.7%. The selected compounds 
were next subjected to the hit confirmation phase in which they were tested at three concentrations (1.0, 3, and 
10 μM) with triplicate data points. Next, on the basis of performance, a response score was computed for each 
compound (i.e., a weighted score averaging the inhibition percentage values at the three tested concentrations) 
and was used to rank the hit confirmation data.
In this way, 1,030 compounds were selected for activity determination (IC50 calculations) because they showed 
response scores >50. During the activity determination assay, full dose-response curves were obtained for eight 
different concentrations in triplicate. Remarkably, 21 compounds were identified as strong blockers with submi-
cromolar IC50 values and entered a lead optimization process. As summarized in Table 1, the hit confirmation 
assay yielded an overall hit rate of 8.78, corresponding to an enrichment factor of 6.27. This EF was calculated 
using a random hit rate of 1.40%, a value that was obtained from previous HTS studies of TRPM8.
Naphthyl derivatives identified as a new class of TRPM8 inhibitors. Among the diverse chemical 
classes selected by SMARTS-based and docking-based strategies, naphthyl derivatives, resulted in the 21 more 
active compounds identified from HTS screening We identified four naphthyl derivatives: one naphthyl derivative 
with an inhibition percentage greater than 50% (compound 1) and three inactive compounds (compounds 2–4) 
(Fig. 4). Naphthyl derivatives are a previously undescribed chemical class of TRPM8 inhibitors and are interesting 
because of their drug-likeness, chemical tractability and potency.
Structure-activity relationships can be inferred through ligand-based speculation; however, the high degree 
of diversity induced by the screening selection criteria prevented the development of a congeneric series (differ-
ent scaffolds) of the naphthyl compounds, and the multiple points of modification in the structure do not allow 
clear structure-activity relationships to be derived. Nevertheless, docking simulations using a TRPM8 homology 
Figure 4. Naphthyl derivatives. Structure and TRPM8 inhibition values for the naphthyl derivatives identified 
by the HTS campaign (the %inhibition values are obtained at 10 mM).
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model were performed for the naphthyl compounds, which enabled some characteristics to be elucidated regard-
ing the role of the different functional groups on the activity of the compounds (Figure S2).
Figure 2 shows in detail the putative complex for compound 1 within the TRPM8 binding site, and provides 
evidence for the key role played by the ionic interaction between the ligand’s ammonium head and Asp802. In 
detail, the naphthyl moiety engages the hydrophobic sub-pocket normally occupied by menthol, a region framed 
by Tyr745, Ile746, Leu806 and Phe809, and elicits π-π stacking and hydrophobic interactions with these residues. 
The positively charged amino group strongly interacts with Asp802 via a salt bridge, and the furan ring is located 
between Leu750 and Phe794 near the amidic group of Asn799. Interestingly, the inactive naphthyl compounds 
also locate in the orthosteric binding site similarly to compound 1, substantially contacting the same key resi-
dues with a common pattern of interactions. However, the major differences common to all inactive compounds 
include the substitution of the amine group with amide. These differences led to i) the consequent loss of flex-
ibility of the central region of the molecule (bringing the polar groups) and, above all, ii) positive charge loss, 
thus weakening the H-bond with Asp802, which, as demonstrated by single point mutagenesis experiments (see 
below), is the key residue for the interaction of this class of molecules.
Pharmacological characterization of compound 1. Analysis of binding mode. To investigate the 
binding mode of our naphthyl TRPM8 antagonist, we generated four different TRPM8 single point mutants. 
The following amino acid positions were selected to be mutated in alanine in separate constructs: Tyr745, Ile746, 
Asn799, and Asp802. Asn799 and Asp802 are required for icilin sensitivity in mammalian TRPM861, whereas 
Tyr745 and Ile746 are the residues involved in activation by menthol and its related molecules, such as Cooling 
agent 1049, 62, 63. Activities of icilin and menthol-related molecule Cooling agent 10 were evaluated on appropri-
ate mutant set (Fig. 5A and B). Data obtained from at least two separate experiments were used to calculate the 
icilin and Cooling agent 10 EC80 values for each TRPM8 mutant to properly activate them in the subsequent 
antagonist-challenge experiments.
As expected, for the Tyr745 and Ile746 mutants, it was not possible to obtain good activation nor by Cooling 
agent 10 neither by icilin62, 63 (Fig. 5A and B); the Tyr745 mutation completely abolished the activation, whereas 
with Ile746, minimal residual activation was still detected. Moreover, mutations of Asn799 and Asp802 in Ala 
completely abolished TRPM8 activation by icilin, thus indicating that these amino acids are necessary for icilin 
binding61 (Fig. 5A); however, these mutations did not affect either maximal TRPM8 activation or EC50 in TRPM8 
activation by Cooling agent 10 (Fig. 5B). On the basis of these results, the activity of compound 1 was evaluated 
for TRPM8 with mutations of the following residues: Ile746 (to assess its ability to inhibit icilin-mediated activa-
tion), and Asn799, Asp802, and Ile746 (to test its ability to inhibit Cooling agent 10 activation).
For the icilin-mediated TRPM8 activation inhibition, the Ile746 substitution significantly (p-value < 0.05) 
shifted the pIC50 of compound 1 from 7.2 to 7.7 (Fig. 6A). By contrast, two different phenomena were detected in 
inhibiting the activation of cooling agent 10 (Fig. 6B). First, Asp802 substitution markedly affected the inhibition 
efficacy of compound 1, shifting its pIC50 from 7.1 to 5.5, almost a 2-fold decrease; second, Asn799 mutation 
Figure 5. Effects of individual TRPM8 point mutations on calcium responses induced by cooling agent 10 
and icilin. Shown data represent mean ± standard error of the mean (SEM) of quadruplicate determinations 
of a representative experiment (n = 4). Statistical analysis was performed using unpaired Student’s t test with 
GraphPad Prism (95% confidence interval). (A) Dose response curves of icilin on mutant TRPM8 receptors. 
The substitutions Y745A, D802A and N799A abrogated agonist activity. The I746A substitution significantly 
(p < 0.05) shifted pIC50 of Icilin from 6.6 to 6.9. (B) Dose response curves of Cooling Agent 10 on mutant 
TRPM8 receptors. The substitution I746A strongly reduced agonist activity in term of efficacy while D802A 
significantly (p < 0.0001) shifted the pIC50 of the agonist from 5.1 to 4.5. Other mutations did not have effects on 
Cooling agent 10 activity.
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enhanced the potency of compound 1 from a pIC50 of 7.1 to 8. If the former effect was expected, the latter effect 
was surprising, because only the K856A mutation has been reported result in a gain of function64. In this case, the 
mutation appears to affect the TRPM8 channel sensitivity in chemical and physically related activation.
A possible explanation for the effect of Asn799 was found by examining the results from the docking exper-
iments and homology modeling. In contrast to Asp802, whose carboxylic function clearly interacts with the 
amine of the ligand, the Asn799 side chain does not bind directly to compound 1. Additionally, docking studies 
suggested that, in the resting state, Asn799 engages the nearby Asp802 side chain with an intramolecular hydro-
gen bond; thus, the alanine mutation, by not allowing this interaction, makes Asp802 more available for the 
interaction with compound 1.
Compound 1 was also tested in schild regression experiments65 and compared with icilin and cooling 
agent (data not shown) to better characterize its mechanism of action. In these experiments, seven points for 
dose-response curves with icilin at seven different concentrations were analyzed. Schild regression analy-
sis of compound 1 versus icilin suggested an orthosteric binding mechanism, causing a right shift of the icilin 
dose-response curves at increasing concentrations of antagonist (data not shown).
These experiments demonstrated that compound 1 binds in the ligand binding pocket of TRPM8 contacting 
Ile746, Asp802 and Asn799. Since we mutated the pocket in which physiological agonists of TRPM8 are described 
to bind and shild regression experiments revealed a right shift of the icilin dose-response curves, we supposed 
that compound 1 act as an orthosteric inhibitor.
Inhibitory activity of compound 1. In HTS compound 1 resulted a potent inhibitor of wild type TRPM8 
so we analyzed its inhibitory behavior in deeper details performing calcium mobilization assays in dose-response 
with different TRPM8 agonists as icilin, cooling agent 10 or cold. Moreover, we also analyzed the inhibitory activ-
ity of compound 1 in experiments with different read out as patch clamp assay.
Compound 1 was found to be a potent inhibitor of TRPM8, showing activity in the nanomolar range in the 
calcium mobilization assay regardless of the agonist used (pIC50 value of 7.38 with Cooling agent 10 and 7.23 with 
icilin) (Fig. 7A).
To further validate the TRPM8 blocking behavior of compound 1 we analyzed its behavior towards the phys-
iological stimulus of TRPM8: cold. Increasing concentrations of compound 1 were incubated with HEK-293/
hTRPM8 cells exposed to a temperature decrease from 25 to 14 °C, and Ca2+ mobilization was recorded with 
Figure 6. Effects of individual TRPM8 point mutations on Compound 1-mediated inhibition of calcium 
responses. Mutant and wt TRPM8-transfected cells were exposed to increasing concentrations of Compound 
1 and then stimulated with icilin (A) or Cooling agent 10 (B) at the specific EC80 concentration. Shown data 
represent mean ± SEM of quadruplicate determinations of a representative experiment (n = 2). Statistical 
analysis was performed using unpaired Student’s t test with GraphPad Prism (95% confidence interval). 
(A) Dose response curves of Compound 1 activity on Icilin activation. The substitution I746A significantly 
(p = 0.003) reduced compound 1 inhibition shifting pIC50 from 7.2 to 7.7. (B) Dose response curves of 
Compound 1 inhibition of Cooling Agent 10 activation of TRPM8 receptor. The substitution D802A shifted its 
pIC50 from 7.2 to 5.5 significantly decreasing (p < 0.0001) Compound 1 potency, while N799A significantly 
increase Compound 1 potency (p < 0.0001) shifting pIC50 from 7.2 to 8.0.
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a Ca2+-sensitive fluorescent dye. In this physiological stimulus assay, compound 1 inhibited TRPM8 activation 
(Fig. 7B) with a pIC50 of 6.76.
In a second orthogonal assay, TRPM8 inhibition by compound 1 was evaluated by manual patch-clamping. 
Outward currents were elicited through the addition of Cooling agent 10 at +40 mV in the presence and absence 
of compound 1. When compound 1 was perfused, the outward current was almost completely blocked, thus sug-
gesting a decrease in TRPM8 activity (Fig. 7C). As expected, after compound 1 was washed out, TRPM8 activity 
was restored.
Remarkably, compound 1 also showed an excellent selectivity profile toward other members of the TRP chan-
nels family, because it was completely inactive on TRPA1, TRPV1 and TRPV4 (Fig. 7D). The three channels 
selected, TRPV1, TRPA1 and TRPV3, have an integrated functional role in common with TRPM8. Moreover, 
TRPV1 and TRPA1 have been associated with side effects including burning and hot flushing.
In conclusion, we demonstrated the inhibitory activity of compound 1 with three different stimuli (icilin, 
cooling agent 10 and cold) and two orthogonal assays (calcium mobilization and manual patch clamp). With all 
stimuli, the IC50 of compound 1 were similar. Additionally, we demonstrated the selectivity of compound one on 
clinically relevant related receptors TRPA1, TRPV1 and TRPV4.
In vivo efficacy of compound 1 in an overactive bladder rat model. To evaluate the potential of com-
pound 1 in the treatment of urologic painful syndromes TRPM8-related we tested its activity in an isovolumetric 
rat bladder model analyzing its effect on MF, inhibition time and threshold volume with or without intravenous 
or intravesical administration of compound 1.
When MF basal values of vehicle-treated and compound 1-treated groups were compared, no significant 
difference between the values was observed (Fig. 8A). Compound 1 significantly decreased MF 0–30 min 
post-administration (p < 0.01; one-way ANOVA with repeated measures followed by Newman-Keul test) 
(Fig. 8A). However, no effect was observed at 30–60 min post-administration. Intravenous administration of 
vehicle did not modify MF. Additionally, after compound 1 administration, the inhibition time of RBC was sig-
nificantly higher than the inhibition time observed after vehicle administration (526 ± 106 versus 204 ± 63 sec; 
p < 0.05; unpaired Student’s t-test) (Fig. 8B). No significant difference between threshold volumes in these two 
groups was observed.
Figure 7. Validation of TRPM8 antagonist compound 1 by orthogonal assays and compound selectivity. (A) 
Seven points dose-response curves of compound 1 inhibition of cooling Agent 10 and Icilin-induced TRPM8 
activation using an intracellular calcium mobilization assay. Compound 1 pIC50s against cooling agent 10 
and icilin are similar (pIC50 7.38 and 7.23 respectively). Shown data represent the mean ± SEM (error bars) 
of triplicate determinations of a representative experiment (n = 2). (B) Dose-response curve of compound 1 
tested by using cold temperatures as stimulus. Compound 1 pIC50 against cold is similar to that calculated for 
chemical agonists (pIC50 6.73). Shown data represent the mean ± SEM (error bars) of triplicate determinations 
of a representative experiment (n = 2). (C) Test of compound 1 activity at manual patch clamp. Outward 
currents were elicited upon addition of cooling agent 10 at + 40 mV, in the presence and in the absence of 
compound 1. Compound 1 addition completely abrogated electrical impulse transmission. (D) Compound 
1 selectivity towards TRPM8 related receptors TRPA1, TRPV1, TRPV4. Compound 1 is completely inactive 
against all TRPM8 related receptors tested (p < 0.001). Shown data represent the mean ± SEM (error bars) of 
triplicate determinations of a representative experiment (n = 2).
www.nature.com/scientificreports/
1 2SCIentIFIC REPORtS | 7: 10999  | DOI:10.1038/s41598-017-11194-0
Intravesical administration of compound 1 (2.268 mg) abolished the occurrence of RBC. Indeed, the maximal 
volume of filling (3 mL) was reached without the occurrence of RBC. Compared with vehicle, the threshold vol-
ume after compound 1 administration was significantly higher (3 mL versus 0.70 ± 0.09 mL) (Fig. 8C).
In conclusion, compound 1 slightly reduced RBC frequency when it was administered by the intravenous 
route but abolished the occurrence of RBC when it was administered intravesically. These results suggest that this 
TRPM8 receptor antagonist inhibits the afferent pathway of the bladder.
Discussion
Although more than 100 papers on the TRPM8 ion channel have been indexed in PubMed in the last year, thus 
revealing the strong interest of the scientific community regarding the role of TRPM8 in many pathological con-
ditions, there is a lack of candidate drugs for further investigation of the potential use of TRPM8 modulators in 
the clinic.
Notably, most of the available TRPM8 antagonists exhibit an unsuitable selectivity profile, which hampers 
their clinical applications; consequently, very few compounds have advanced to clinical trials66, 67. Only three 
compounds, PF-0510567966 (ClinicalTrials.gov Identifier: NCT01393652) from Pfizer, AMG-333 (ClinicalTrials.
gov Identifier: NCT01953341) from Amgen, and the cannabinoid Cannabidivarin (GWP-42006) (ClinicalTrials.
gov Identifier: NCT02365610) from GW Pharmaceuticals, have entered clinical trials. However, PF-05105679 
was discontinued because of side effects, and results of the AMG-33 trial have not yet been disclosed even though 
the study ended in September of 2014. Given this landscape, the naphthyl analogs reported here may provide a 
good balance of potency and selectivity, thus decreasing unfavorable off-target effects and representing valuable 
candidates for clinical studies.
Here we used two virtual screening approaches in combination: one ligand-based approach using SMARTS 
strings as a pharmacophoric filter and one structure-based approach using molecular docking techniques on 
a validated homology model to identify a novel class of TRPM8 inhibitors with clinics suitable characteristics. 
Analysis of the screening results highlighted the beneficial effects of combining ligand- and structure-based meth-
ods. As detailed in Table 2, the compounds identified by both methods included 126 confirmed hits, thus yielding 
an enhanced enrichment factor of 8.4. Hence, the two methods, while covering a diverse chemical space, can be 
successfully combined in a parallel approach, thereby allowing the selection of only compounds able to form the 
most stable complexes from among the compounds fulfilling the pharmacophore filters. Ligand-based approach 
are limited by the selection of compounds used to derive the pharmacophore, so is likely that with this approach it 
would be found molecules similar to those selected at the beginning, on the other hand structure-based approach 
is limited by a rigid conformation of the receptor which selected only molecules which would fit in such rigid 
structure. A combined approach covers a wide chemical space and can identify different chemical classes of 
TRPM8 inhibitors.
Figure 8. In vivo effects of compound 1 in isovolumetric bladder rat model. The results were given as mean 
values ± standard error of the mean (sem) of the measurement in 8 different rats. (A) Effects of intravenous 
administration of vehicle (on the left) and compound 1 at 10 mg/kg (on the right) on micturition frequency 
(MF). No significant changes were observed upon vehicle administration (on the left), while compound 1 (on 
the right) significantly reduced MF at 30 min (p < 0.01). (B) Effects of intravenous administration of vehicle and 
compound 1 at 10 mg/kg on inhibition time. Compound 1 significantly enhanced inhibition time (p < 0.05). 
(C) Effects of intravescical administration of vehicle and compound 1 at 2.268 mg. Compound 1 significantly 
increased (p < 0.01) the threshold volume inducing RBC.
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With the described combined in silico approach, we identified naphthyl derivatives as a promising novel chem-
ical class of TRPM8 inhibitors. To date, approximately 120 different chemotypes can be enumerated among all 
known TRPM8 antagonists47. These chemotypes include the following examples: benzyloxybenzene derivatives, 
such as AMTB (Bayer)68, Cpd 87 (Glenmark, WO2010010435) and Cpd 14 (Pfizer)69; arylamides, arylsulfona-
mides and close analogs, such as RQ-00203078705047 (RaQualia)51 and Cpd 7 s (Janssen)70; AMGEN tetrahydroi-
soquinolines derivatives71; chromanes and chromenes, such as Cpd 8f (Glenmark)24 and Cannabichromene (GW 
Pharmaceuticals)72, respectively; azetidin-2-ones23; and diphenylpyrazoles (Kissei, WO2016208602) Napththyl 
derivatives have the proper chemical characteristics and tractability to overcome the lead optimization process. 
The compound 1 lead presented in this paper demonstrated to be potent and selective before any chemical opti-
mization. Moreover, in in vivo proof of concept compound 1 had adequate PK/ADME properties and presented a 
positive outcome in approaching the treatment of painful syndromes in urologic field, thus supporting the further 
optimization of this compound.
It is noteworthy that compound 1 didn’t have any effect on inhibition of three selected TRP channels, namely 
TRPV1, TRPA1 and TRPV3. The three channels selected for the selectivity study share with TRPM8 an integrated 
role in pain, inflammation, and cancer14, and they can be co-regulated by prolactin4, 10, 73. TRPV1, TRPA1, TRPV3 
and TRPM8 are expressed in distinct populations of primary afferent neurons and have been demonstrated to 
mediate hypersensitivity to thermal, mechanical and chemical stimuli after tissue and nerve injury and inflam-
mation11, 74, 75. Most TRPV1 neurons also express TRPA1, whereas TRPM8 neurons are different from TRPV1/
TRPA1 fibers76. The selected receptors have been demonstrated to play a pivotal role in nociception and hence 
are potential targets of new analgesic therapeutics; however, ligands are often poorly selective toward these TRP 
receptors. Additionally, because TRPV1 and TRPA1 have been associated with side effects such as burning sensa-
tions, the reported side effects because of which PF-05105679 has been retired from clinical testing77–80, enhanced 
selectivity toward these receptors may provide a good starting point for avoiding these adverse effects.
In conclusion, we present a case study of the benefits of a combined in silico approach to increase the enrich-
ment factor of screening campaigns for new lead compounds. Our approach identified a new class of potent and 
selective TRPM8 inhibitors belonging to the class of naphthyl derivatives that may be developed as clinical candi-
dates because of their favorable pharmacological profiles (potency, efficacy, selectivity and chemical tractability).
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